Tethys Announces Data Presentations on PreDx® DRS at 2011 American Diabetes Association 71st Scientific Sessions

June 20, 2011

EMERYVILLE, Calif.--Tethys Bioscience, Inc. announces that data from two studies of the company’s PreDx® Diabetes Risk Score (DRS) will be presented in poster sessions at the upcoming American Diabetes Association 71st Scientific Sessions to be held June 24-28, 2011 in San Diego.

Saturday, June 25th: 11:30 am – 1:30 pm PDT, Hall B

Abstract number 829-P

Poster-22: Psychosocial-Behavioral Medicine (session code PO44)

“Changes and Correlations with PreDx® Diabetes Risk Score Following Brief Residential Behavioral Weight Loss” will be presented by Jennifer Pells, PhD, Program Facilitator, Structure House (Durham, NC).

Sunday, June 26th: 12 noon – 2:00 pm PDT, Hall B

Abstract number 1331-P

Poster-09: Epidemiology (session code PO13)

“Changes in a Diabetes Risk Score Due to Intensive Lifestyle Intervention in the European Diabetes Prevention Study (EDIPS) will be presented by Professor Jaakko Tuomilehto, MD, PhD, University of Helsinki (Helsinki, Finland).

About Tethys
Tethys is a cardiometabolic diagnostics company that creates and commercializes breakthrough biomarker-based blood tests that predict imminent disease risk and enable targeted intervention to preempt the onset of chronic conditions such as type 2 diabetes. Tethys introduced its first product -- PreDx® Diabetes Risk Score -- to the market in 2008, and initiated sales in 2009. The Tethys PreDx platform includes products in development to determine risk for first-time heart attack, osteoporotic fracture and other cardiometabolic diseases with the goal of improving health outcomes and reducing the devastating economic impact that debilitating, preventable diseases have on individuals and society. The PreDx DRS is performed solely at the Tethys Bioscience Clinical Laboratory in Emeryville, CA. For more information about Tethys and PreDx DRS, please visit www.tethysbio.com.